Guide to How Stem Cell Therapy Works

Reviewed by Dr. Ankeet Choxi and Jarred Mait, MD

Stem cell therapy is often discussed as a single idea, but in practice it is a multi-step medical workflow. At STEMS Health, patient education focuses on understanding that outcomes are influenced not just by the cells themselves, but by how those cells are sourced, handled, delivered, and how the body responds afterward.

This guide walks through the full process – starting with evaluation and cell sourcing, moving through laboratory handling and delivery, and ending with how cells or their signals may support repair and regeneration in damaged tissues. The goal is to explain each step clearly, using plain language and without overpromising results.

What “Stem Cell Therapy” Means in Practical Terms

In clinical settings, “stem cell therapy” refers to the use of biologic cells or cell-derived materials as part of a regenerative care plan. The term can encompass different cell sources, processing methods, and delivery routes, depending on the condition being addressed and the protocol being used.

Importantly, stem cell therapy is not a single standardized treatment. Two patients may both be described as receiving stem cell–based care, yet their workflows – from sourcing to delivery – may differ substantially. Understanding those differences helps patients ask informed questions and better interpret claims.

This article outlines the general workflow used in regenerative medicine settings and highlights why process transparency matters.

Step 1  –  Patient Evaluation and Treatment Planning

Before any discussion of cells, regenerative care begins with a medical evaluation. Clinicians assess whether stem cell–based approaches are being considered and whether a patient may be an appropriate candidate.

This evaluation typically includes:

• A review of medical history and current medications
• Physical examination focused on pain, mobility, and function
• Imaging studies such as X-ray, MRI, or ultrasound when appropriate
• Discussion of prior treatments and response

The goal is not to “sell” a therapy, but to understand the underlying problem. Structural damage, inflammatory conditions, and degenerative changes can behave very differently, even when symptoms appear similar.

Baseline measurements – such as pain scores, range of motion, or activity limitations – are often documented so changes can be evaluated over time.

Conditions Commonly Discussed in Regenerative Care Settings

Stem cell therapy is most often discussed in the context of musculoskeletal concerns, such as joint pain, tendon or ligament injuries, and certain spine-related conditions. These discussions focus on tissue quality, inflammation, and function rather than a single diagnosis alone.

Clinicians also screen for situations where regenerative therapies may not be appropriate, such as active infection, certain systemic illnesses, or conditions requiring immediate surgical intervention.

Why Imaging and Guidance Matter

Imaging plays two roles: diagnosis and delivery planning. Ultrasound, in particular, allows clinicians to visualize soft tissues and joints in real time. When injections are used, ultrasound guidance helps confirm accurate placement and provides documentation of where biologic material was delivered.

Step 2  –  Stem Cell Sourcing

Once a care plan is established, the next step is stem cell sourcing – where the cells come from. Broadly, stem cells fall into two categories based on origin: autologous and allogeneic.

Autologous cells come from the patient. Allogeneic cells come from a donor. Each approach has practical and regulatory considerations.

Autologous Stem Cells

Autologous stem cells are collected from the patient’s own tissue. Commonly referenced sources include bone marrow and adipose (fat) tissue. These tissues contain populations of adult stem cells and supportive cells.

Because the cells originate from the patient, compatibility concerns are minimized. Autologous sourcing often involves a same-day workflow, where cells are collected, processed, and delivered during a single visit, depending on protocol.

From a patient perspective, this step is best understood as a collection process rather than a surgery. The specifics vary, and clinicians explain what to expect during consultation.

Allogeneic Stem Cells

Allogeneic stem cells are derived from screened donors. These cells are processed and stored according to established standards before being distributed for clinical or research use.

Donor screening, testing, and documentation are central to this approach. Allogeneic products may be used when standardization, availability, or logistical considerations are prioritized.

Clinics discuss sourcing transparently so patients understand whether cells are autologous or donor-derived and why a particular source is being considered.

Chain of Custody and Documentation

Regardless of source, chain of custody matters. This refers to the tracking and documentation of biologic material from collection through delivery. Proper labeling, handling, and record-keeping help support safety, traceability, and accountability throughout the process.

Step 3  –  Lab Processing and Handling

After sourcing, cells undergo laboratory processing. Processing does not mean the same thing in all settings. It can range from minimal preparation to more complex laboratory workflows conducted in regulated environments.

At a high level, processing prepares biologic material for safe and consistent delivery.

Cell Isolation and Concentration

Isolation refers to separating specific cellular components from collected tissue. Concentration refers to increasing the proportion of target cells within a sample.

These steps aim to standardize what is delivered. Rather than injecting raw tissue, processing helps ensure that the material contains a defined cellular profile appropriate for the intended use.

Quality Controls in Handling

Quality control measures vary by protocol but often include:

• Viability checks, confirming that cells are intact and functional
• Sterility practices, designed to reduce contamination risk
• Time and temperature controls to preserve biologic integrity

These steps are less visible to patients but play a central role in safety and consistency.

Cryopreservation and Storage

In some workflows, biologic material is used the same day it is collected. In others, it may be stored for later use through cryopreservation, or controlled freezing.

Cryopreservation allows cells to be stored and later thawed under specific conditions. Proper storage requires traceability and careful handling during re-preparation to maintain cell quality.

Step 4  –  Delivery Into the Body

Delivery refers to how and where cells or biologic material are introduced into the body. The route of delivery is chosen based on the tissue being addressed and the clinical goal.

Targeted Injection Into Tissue or Joints

For many musculoskeletal concerns, delivery involves injection into a specific joint or soft-tissue structure. Ultrasound guidance is commonly used to confirm accurate placement.

From a patient standpoint, this step is often similar to other image-guided injections. The experience typically involves local preparation, brief discomfort, and post-procedure instructions focused on activity modification.

IV Infusion Versus Local Injection

Some protocols use intravenous (IV) infusion rather than local injection. IV delivery introduces biologic material into the bloodstream, allowing systemic circulation.

Local injections aim to deliver material directly to a target tissue, while IV approaches rely on broader distribution and biologic signaling. The choice between these routes depends on clinical rationale rather than a one-size-fits-all rule.

Step 5  –  What Happens After Delivery

One of the most common questions patients ask is whether stem cells “turn into new tissue.” In reality, regenerative responses can involve multiple mechanisms, and outcomes vary.

Research and clinical discussions generally focus on two broad effects: direct cellular activity and indirect signaling effects.

Homing and the Tissue Microenvironment

“Homing” refers to the tendency of cells or signals to localize toward areas of injury or inflammation. Damaged tissues release chemical cues that differ from healthy tissue.

The tissue microenvironment – including oxygen levels, blood supply, inflammation, and mechanical stress – plays a major role in how biologic material behaves after delivery.

Paracrine Signaling

Paracrine signaling describes how cells release substances that influence nearby cells. Rather than becoming replacement tissue themselves, delivered cells may act more like coordinators.

An analogy often used in regenerative medicine is that of a foreman on a repair site: instead of doing every repair directly, the foreman sends instructions that guide other workers. In this case, signaling molecules can influence inflammation, cellular activity, and tissue responses.

Immunomodulation and Inflammation Response

Inflammation is part of the body’s natural healing process, but excessive or prolonged inflammation can impair recovery. Immunomodulation refers to influencing immune responses toward balance rather than suppression.

Some regenerative approaches are studied for how they interact with inflammatory pathways, which may relate to symptom changes such as pain or stiffness. These effects depend on individual biology and condition severity.

Extracellular Vesicles and Other Signals

Cells also release microscopic packages called extracellular vesicles. These vesicles carry proteins and genetic material that can influence nearby cells.

Angiogenesis, or support for new blood vessel formation, is another area of study in regenerative research. Improved blood supply can affect how tissues receive nutrients and oxygen during repair.

These mechanisms remain areas of ongoing investigation rather than guaranteed outcomes.

Step 6  –  Healing Timeline and Follow-Up

Regenerative processes are not instantaneous. Patients are often advised that changes may occur gradually over weeks or months.

Early changes may include temporary soreness or inflammation related to the delivery itself. Later changes may involve gradual improvements in function or comfort, depending on individual factors.

Follow-up appointments allow clinicians to assess progress relative to baseline measurements. In some cases, physical therapy or guided rehabilitation is recommended to support functional recovery.

Factors that may influence outcomes include:

• Severity and duration of the underlying condition
• Overall health and metabolic status
• Activity modification and rehabilitation adherence
• Tissue type involved (cartilage, tendon, muscle)

Safety, Risks, and Regulatory Considerations

As with any medical procedure, stem cell–based therapies carry potential risks. These may include infection, bleeding, localized pain, or inflammatory flare. Screening and sterile handling practices aim to reduce these risks.

Clinics are responsible for:

• Appropriate patient selection
• Clear informed consent
• Accurate documentation
• Avoiding claims not supported by evidence

Patients are encouraged to ask detailed questions about sourcing, processing, delivery, and follow-up expectations.

Reading Stem Cell Claims With a Practical Lens

Because regenerative medicine is a rapidly evolving field, claims can vary widely in clarity and accuracy. Practical indicators of transparent care include:

• Clear explanation of cell source
• Defined handling and delivery methods
• Discussion of realistic goals rather than guarantees
• Willingness to discuss limitations and uncertainties

At STEMS Health, educational content is designed to help patients better understand the process so discussions can be grounded in evidence and individualized care planning.

A Clear View of the Full Workflow

Stem cell therapy is best understood as a process rather than a single event. From evaluation and sourcing to lab handling, delivery, and post-treatment biology, each step plays a role in how the body responds.

For readers of the STEMS Health blog, understanding this workflow provides a clearer framework for evaluating regenerative care options and engaging in informed conversations with licensed providers.

Disclaimer

The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

Stem cell therapy is often discussed as a single idea, but in practice it is a multi-step medical workflow. At STEMS Health, patient education focuses on understanding that outcomes are influenced not just by the cells themselves, but by how those cells are sourced, handled, delivered, and how the body responds afterward.

This guide walks through the full process – starting with evaluation and cell sourcing, moving through laboratory handling and delivery, and ending with how cells or their signals may support repair and regeneration in damaged tissues. The goal is to explain each step clearly, using plain language and without overpromising results.

What “Stem Cell Therapy” Means in Practical Terms

In clinical settings, “stem cell therapy” refers to the use of biologic cells or cell-derived materials as part of a regenerative care plan. The term can encompass different cell sources, processing methods, and delivery routes, depending on the condition being addressed and the protocol being used.

Importantly, stem cell therapy is not a single standardized treatment. Two patients may both be described as receiving stem cell–based care, yet their workflows – from sourcing to delivery – may differ substantially. Understanding those differences helps patients ask informed questions and better interpret claims.

This article outlines the general workflow used in regenerative medicine settings and highlights why process transparency matters.

Step 1  –  Patient Evaluation and Treatment Planning

Before any discussion of cells, regenerative care begins with a medical evaluation. Clinicians assess whether stem cell–based approaches are being considered and whether a patient may be an appropriate candidate.

This evaluation typically includes:

• A review of medical history and current medications
• Physical examination focused on pain, mobility, and function
• Imaging studies such as X-ray, MRI, or ultrasound when appropriate
• Discussion of prior treatments and response

The goal is not to “sell” a therapy, but to understand the underlying problem. Structural damage, inflammatory conditions, and degenerative changes can behave very differently, even when symptoms appear similar.

Baseline measurements – such as pain scores, range of motion, or activity limitations – are often documented so changes can be evaluated over time.

Conditions Commonly Discussed in Regenerative Care Settings

Stem cell therapy is most often discussed in the context of musculoskeletal concerns, such as joint pain, tendon or ligament injuries, and certain spine-related conditions. These discussions focus on tissue quality, inflammation, and function rather than a single diagnosis alone.

Clinicians also screen for situations where regenerative therapies may not be appropriate, such as active infection, certain systemic illnesses, or conditions requiring immediate surgical intervention.

Why Imaging and Guidance Matter

Imaging plays two roles: diagnosis and delivery planning. Ultrasound, in particular, allows clinicians to visualize soft tissues and joints in real time. When injections are used, ultrasound guidance helps confirm accurate placement and provides documentation of where biologic material was delivered.

Step 2  –  Stem Cell Sourcing

Once a care plan is established, the next step is stem cell sourcing – where the cells come from. Broadly, stem cells fall into two categories based on origin: autologous and allogeneic.

Autologous cells come from the patient. Allogeneic cells come from a donor. Each approach has practical and regulatory considerations.

Autologous Stem Cells

Autologous stem cells are collected from the patient’s own tissue. Commonly referenced sources include bone marrow and adipose (fat) tissue. These tissues contain populations of adult stem cells and supportive cells.

Because the cells originate from the patient, compatibility concerns are minimized. Autologous sourcing often involves a same-day workflow, where cells are collected, processed, and delivered during a single visit, depending on protocol.

From a patient perspective, this step is best understood as a collection process rather than a surgery. The specifics vary, and clinicians explain what to expect during consultation.

Allogeneic Stem Cells

Allogeneic stem cells are derived from screened donors. These cells are processed and stored according to established standards before being distributed for clinical or research use.

Donor screening, testing, and documentation are central to this approach. Allogeneic products may be used when standardization, availability, or logistical considerations are prioritized.

Clinics discuss sourcing transparently so patients understand whether cells are autologous or donor-derived and why a particular source is being considered.

Chain of Custody and Documentation

Regardless of source, chain of custody matters. This refers to the tracking and documentation of biologic material from collection through delivery. Proper labeling, handling, and record-keeping help support safety, traceability, and accountability throughout the process.

Step 3  –  Lab Processing and Handling

After sourcing, cells undergo laboratory processing. Processing does not mean the same thing in all settings. It can range from minimal preparation to more complex laboratory workflows conducted in regulated environments.

At a high level, processing prepares biologic material for safe and consistent delivery.

Cell Isolation and Concentration

Isolation refers to separating specific cellular components from collected tissue. Concentration refers to increasing the proportion of target cells within a sample.

These steps aim to standardize what is delivered. Rather than injecting raw tissue, processing helps ensure that the material contains a defined cellular profile appropriate for the intended use.

Quality Controls in Handling

Quality control measures vary by protocol but often include:

• Viability checks, confirming that cells are intact and functional
• Sterility practices, designed to reduce contamination risk
• Time and temperature controls to preserve biologic integrity

These steps are less visible to patients but play a central role in safety and consistency.

Cryopreservation and Storage

In some workflows, biologic material is used the same day it is collected. In others, it may be stored for later use through cryopreservation, or controlled freezing.

Cryopreservation allows cells to be stored and later thawed under specific conditions. Proper storage requires traceability and careful handling during re-preparation to maintain cell quality.

Step 4  –  Delivery Into the Body

Delivery refers to how and where cells or biologic material are introduced into the body. The route of delivery is chosen based on the tissue being addressed and the clinical goal.

Targeted Injection Into Tissue or Joints

For many musculoskeletal concerns, delivery involves injection into a specific joint or soft-tissue structure. Ultrasound guidance is commonly used to confirm accurate placement.

From a patient standpoint, this step is often similar to other image-guided injections. The experience typically involves local preparation, brief discomfort, and post-procedure instructions focused on activity modification.

IV Infusion Versus Local Injection

Some protocols use intravenous (IV) infusion rather than local injection. IV delivery introduces biologic material into the bloodstream, allowing systemic circulation.

Local injections aim to deliver material directly to a target tissue, while IV approaches rely on broader distribution and biologic signaling. The choice between these routes depends on clinical rationale rather than a one-size-fits-all rule.

Step 5  –  What Happens After Delivery

One of the most common questions patients ask is whether stem cells “turn into new tissue.” In reality, regenerative responses can involve multiple mechanisms, and outcomes vary.

Research and clinical discussions generally focus on two broad effects: direct cellular activity and indirect signaling effects.

Homing and the Tissue Microenvironment

“Homing” refers to the tendency of cells or signals to localize toward areas of injury or inflammation. Damaged tissues release chemical cues that differ from healthy tissue.

The tissue microenvironment – including oxygen levels, blood supply, inflammation, and mechanical stress – plays a major role in how biologic material behaves after delivery.

Paracrine Signaling

Paracrine signaling describes how cells release substances that influence nearby cells. Rather than becoming replacement tissue themselves, delivered cells may act more like coordinators.

An analogy often used in regenerative medicine is that of a foreman on a repair site: instead of doing every repair directly, the foreman sends instructions that guide other workers. In this case, signaling molecules can influence inflammation, cellular activity, and tissue responses.

Immunomodulation and Inflammation Response

Inflammation is part of the body’s natural healing process, but excessive or prolonged inflammation can impair recovery. Immunomodulation refers to influencing immune responses toward balance rather than suppression.

Some regenerative approaches are studied for how they interact with inflammatory pathways, which may relate to symptom changes such as pain or stiffness. These effects depend on individual biology and condition severity.

Extracellular Vesicles and Other Signals

Cells also release microscopic packages called extracellular vesicles. These vesicles carry proteins and genetic material that can influence nearby cells.

Angiogenesis, or support for new blood vessel formation, is another area of study in regenerative research. Improved blood supply can affect how tissues receive nutrients and oxygen during repair.

These mechanisms remain areas of ongoing investigation rather than guaranteed outcomes.

Step 6  –  Healing Timeline and Follow-Up

Regenerative processes are not instantaneous. Patients are often advised that changes may occur gradually over weeks or months.

Early changes may include temporary soreness or inflammation related to the delivery itself. Later changes may involve gradual improvements in function or comfort, depending on individual factors.

Follow-up appointments allow clinicians to assess progress relative to baseline measurements. In some cases, physical therapy or guided rehabilitation is recommended to support functional recovery.

Factors that may influence outcomes include:

• Severity and duration of the underlying condition
• Overall health and metabolic status
• Activity modification and rehabilitation adherence
• Tissue type involved (cartilage, tendon, muscle)

Safety, Risks, and Regulatory Considerations

As with any medical procedure, stem cell–based therapies carry potential risks. These may include infection, bleeding, localized pain, or inflammatory flare. Screening and sterile handling practices aim to reduce these risks.

Clinics are responsible for:

• Appropriate patient selection
• Clear informed consent
• Accurate documentation
• Avoiding claims not supported by evidence

Patients are encouraged to ask detailed questions about sourcing, processing, delivery, and follow-up expectations.

Reading Stem Cell Claims With a Practical Lens

Because regenerative medicine is a rapidly evolving field, claims can vary widely in clarity and accuracy. Practical indicators of transparent care include:

• Clear explanation of cell source
• Defined handling and delivery methods
• Discussion of realistic goals rather than guarantees
• Willingness to discuss limitations and uncertainties

At STEMS Health, educational content is designed to help patients better understand the process so discussions can be grounded in evidence and individualized care planning.

A Clear View of the Full Workflow

Stem cell therapy is best understood as a process rather than a single event. From evaluation and sourcing to lab handling, delivery, and post-treatment biology, each step plays a role in how the body responds.

For readers of the STEMS Health blog, understanding this workflow provides a clearer framework for evaluating regenerative care options and engaging in informed conversations with licensed providers.

Disclaimer

The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

Stem cell therapy is often discussed as a single idea, but in practice it is a multi-step medical workflow. At STEMS Health, patient education focuses on understanding that outcomes are influenced not just by the cells themselves, but by how those cells are sourced, handled, delivered, and how the body responds afterward.

This guide walks through the full process – starting with evaluation and cell sourcing, moving through laboratory handling and delivery, and ending with how cells or their signals may support repair and regeneration in damaged tissues. The goal is to explain each step clearly, using plain language and without overpromising results.

What “Stem Cell Therapy” Means in Practical Terms

In clinical settings, “stem cell therapy” refers to the use of biologic cells or cell-derived materials as part of a regenerative care plan. The term can encompass different cell sources, processing methods, and delivery routes, depending on the condition being addressed and the protocol being used.

Importantly, stem cell therapy is not a single standardized treatment. Two patients may both be described as receiving stem cell–based care, yet their workflows – from sourcing to delivery – may differ substantially. Understanding those differences helps patients ask informed questions and better interpret claims.

This article outlines the general workflow used in regenerative medicine settings and highlights why process transparency matters.

Step 1  –  Patient Evaluation and Treatment Planning

Before any discussion of cells, regenerative care begins with a medical evaluation. Clinicians assess whether stem cell–based approaches are being considered and whether a patient may be an appropriate candidate.

This evaluation typically includes:

• A review of medical history and current medications
• Physical examination focused on pain, mobility, and function
• Imaging studies such as X-ray, MRI, or ultrasound when appropriate
• Discussion of prior treatments and response

The goal is not to “sell” a therapy, but to understand the underlying problem. Structural damage, inflammatory conditions, and degenerative changes can behave very differently, even when symptoms appear similar.

Baseline measurements – such as pain scores, range of motion, or activity limitations – are often documented so changes can be evaluated over time.

Conditions Commonly Discussed in Regenerative Care Settings

Stem cell therapy is most often discussed in the context of musculoskeletal concerns, such as joint pain, tendon or ligament injuries, and certain spine-related conditions. These discussions focus on tissue quality, inflammation, and function rather than a single diagnosis alone.

Clinicians also screen for situations where regenerative therapies may not be appropriate, such as active infection, certain systemic illnesses, or conditions requiring immediate surgical intervention.

Why Imaging and Guidance Matter

Imaging plays two roles: diagnosis and delivery planning. Ultrasound, in particular, allows clinicians to visualize soft tissues and joints in real time. When injections are used, ultrasound guidance helps confirm accurate placement and provides documentation of where biologic material was delivered.

Step 2  –  Stem Cell Sourcing

Once a care plan is established, the next step is stem cell sourcing – where the cells come from. Broadly, stem cells fall into two categories based on origin: autologous and allogeneic.

Autologous cells come from the patient. Allogeneic cells come from a donor. Each approach has practical and regulatory considerations.

Autologous Stem Cells

Autologous stem cells are collected from the patient’s own tissue. Commonly referenced sources include bone marrow and adipose (fat) tissue. These tissues contain populations of adult stem cells and supportive cells.

Because the cells originate from the patient, compatibility concerns are minimized. Autologous sourcing often involves a same-day workflow, where cells are collected, processed, and delivered during a single visit, depending on protocol.

From a patient perspective, this step is best understood as a collection process rather than a surgery. The specifics vary, and clinicians explain what to expect during consultation.

Allogeneic Stem Cells

Allogeneic stem cells are derived from screened donors. These cells are processed and stored according to established standards before being distributed for clinical or research use.

Donor screening, testing, and documentation are central to this approach. Allogeneic products may be used when standardization, availability, or logistical considerations are prioritized.

Clinics discuss sourcing transparently so patients understand whether cells are autologous or donor-derived and why a particular source is being considered.

Chain of Custody and Documentation

Regardless of source, chain of custody matters. This refers to the tracking and documentation of biologic material from collection through delivery. Proper labeling, handling, and record-keeping help support safety, traceability, and accountability throughout the process.

Step 3  –  Lab Processing and Handling

After sourcing, cells undergo laboratory processing. Processing does not mean the same thing in all settings. It can range from minimal preparation to more complex laboratory workflows conducted in regulated environments.

At a high level, processing prepares biologic material for safe and consistent delivery.

Cell Isolation and Concentration

Isolation refers to separating specific cellular components from collected tissue. Concentration refers to increasing the proportion of target cells within a sample.

These steps aim to standardize what is delivered. Rather than injecting raw tissue, processing helps ensure that the material contains a defined cellular profile appropriate for the intended use.

Quality Controls in Handling

Quality control measures vary by protocol but often include:

• Viability checks, confirming that cells are intact and functional
• Sterility practices, designed to reduce contamination risk
• Time and temperature controls to preserve biologic integrity

These steps are less visible to patients but play a central role in safety and consistency.

Cryopreservation and Storage

In some workflows, biologic material is used the same day it is collected. In others, it may be stored for later use through cryopreservation, or controlled freezing.

Cryopreservation allows cells to be stored and later thawed under specific conditions. Proper storage requires traceability and careful handling during re-preparation to maintain cell quality.

Step 4  –  Delivery Into the Body

Delivery refers to how and where cells or biologic material are introduced into the body. The route of delivery is chosen based on the tissue being addressed and the clinical goal.

Targeted Injection Into Tissue or Joints

For many musculoskeletal concerns, delivery involves injection into a specific joint or soft-tissue structure. Ultrasound guidance is commonly used to confirm accurate placement.

From a patient standpoint, this step is often similar to other image-guided injections. The experience typically involves local preparation, brief discomfort, and post-procedure instructions focused on activity modification.

IV Infusion Versus Local Injection

Some protocols use intravenous (IV) infusion rather than local injection. IV delivery introduces biologic material into the bloodstream, allowing systemic circulation.

Local injections aim to deliver material directly to a target tissue, while IV approaches rely on broader distribution and biologic signaling. The choice between these routes depends on clinical rationale rather than a one-size-fits-all rule.

Step 5  –  What Happens After Delivery

One of the most common questions patients ask is whether stem cells “turn into new tissue.” In reality, regenerative responses can involve multiple mechanisms, and outcomes vary.

Research and clinical discussions generally focus on two broad effects: direct cellular activity and indirect signaling effects.

Homing and the Tissue Microenvironment

“Homing” refers to the tendency of cells or signals to localize toward areas of injury or inflammation. Damaged tissues release chemical cues that differ from healthy tissue.

The tissue microenvironment – including oxygen levels, blood supply, inflammation, and mechanical stress – plays a major role in how biologic material behaves after delivery.

Paracrine Signaling

Paracrine signaling describes how cells release substances that influence nearby cells. Rather than becoming replacement tissue themselves, delivered cells may act more like coordinators.

An analogy often used in regenerative medicine is that of a foreman on a repair site: instead of doing every repair directly, the foreman sends instructions that guide other workers. In this case, signaling molecules can influence inflammation, cellular activity, and tissue responses.

Immunomodulation and Inflammation Response

Inflammation is part of the body’s natural healing process, but excessive or prolonged inflammation can impair recovery. Immunomodulation refers to influencing immune responses toward balance rather than suppression.

Some regenerative approaches are studied for how they interact with inflammatory pathways, which may relate to symptom changes such as pain or stiffness. These effects depend on individual biology and condition severity.

Extracellular Vesicles and Other Signals

Cells also release microscopic packages called extracellular vesicles. These vesicles carry proteins and genetic material that can influence nearby cells.

Angiogenesis, or support for new blood vessel formation, is another area of study in regenerative research. Improved blood supply can affect how tissues receive nutrients and oxygen during repair.

These mechanisms remain areas of ongoing investigation rather than guaranteed outcomes.

Step 6  –  Healing Timeline and Follow-Up

Regenerative processes are not instantaneous. Patients are often advised that changes may occur gradually over weeks or months.

Early changes may include temporary soreness or inflammation related to the delivery itself. Later changes may involve gradual improvements in function or comfort, depending on individual factors.

Follow-up appointments allow clinicians to assess progress relative to baseline measurements. In some cases, physical therapy or guided rehabilitation is recommended to support functional recovery.

Factors that may influence outcomes include:

• Severity and duration of the underlying condition
• Overall health and metabolic status
• Activity modification and rehabilitation adherence
• Tissue type involved (cartilage, tendon, muscle)

Safety, Risks, and Regulatory Considerations

As with any medical procedure, stem cell–based therapies carry potential risks. These may include infection, bleeding, localized pain, or inflammatory flare. Screening and sterile handling practices aim to reduce these risks.

Clinics are responsible for:

• Appropriate patient selection
• Clear informed consent
• Accurate documentation
• Avoiding claims not supported by evidence

Patients are encouraged to ask detailed questions about sourcing, processing, delivery, and follow-up expectations.

Reading Stem Cell Claims With a Practical Lens

Because regenerative medicine is a rapidly evolving field, claims can vary widely in clarity and accuracy. Practical indicators of transparent care include:

• Clear explanation of cell source
• Defined handling and delivery methods
• Discussion of realistic goals rather than guarantees
• Willingness to discuss limitations and uncertainties

At STEMS Health, educational content is designed to help patients better understand the process so discussions can be grounded in evidence and individualized care planning.

A Clear View of the Full Workflow

Stem cell therapy is best understood as a process rather than a single event. From evaluation and sourcing to lab handling, delivery, and post-treatment biology, each step plays a role in how the body responds.

For readers of the STEMS Health blog, understanding this workflow provides a clearer framework for evaluating regenerative care options and engaging in informed conversations with licensed providers.

Disclaimer

The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.